| Palmitoylacyltransferase Zdhhc9 inactivation mitigates leukemogenic potential of oncogenic Nras. | None |
| Bombesin stimulation of inositol 1,4,5-trisphosphate generation and intracellular calcium release is amplified in a cell line overexpressing the N-ras proto-oncogene. | None |
| The N-ras oncogene is activated in a human medulloblastoma cell line. | None |
| Oncogene NRAS G138R variant was identified as having a predicted damaging effect on protein function. | None |
| Results show that promoter mutations render telomerase reverse transcriptase (TERT) expression dependent on MAPK signal pathway activation due to oncogenic BRAF or NRAS mutations. | None |
| Studies indicate that RAS proteins were among the first oncogenes identified and are mutationally activated in 30% of all cancer types. | None |
| These findings highlight a novel mechanism for resistance to ER-stress through oncogenic activation of MEK/ERK signalling by RAC1 and NRAS. | None |
| Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells. | None |
| Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. | None |
| Causal role for an activated N-ras oncogene in the induction of tumorigenicity acquired by a human cell line. | None |
| MicroRNA-22 targeted NRAS proto-oncogene. | None |
| Analysis of RAS oncogene mutations in human lymphoid malignancies. | None |
| Ectopic introduction of SPRY4 recapitulated the growth arrest phenotype of dual BRAF(V600E)/NRAS(Q61) expression while SPRY4 depletion led to a partial rescue from oncogenic antagonism. | None |
| Dissociation of c-fos from ODC expression and neuronal differentiation in a PC12 subline stably transfected with an inducible N-ras oncogene. | None |
| A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. | None |
| Mutations of the Kirsten-ras proto-oncogene in human preleukaemia. | None |
| Clonal diversity of the Kirsten-ras oncogene during tumor progression in athymic nude mice: mechanisms of amplification and rearrangement. | None |
| The oncogenic forms of N-ras or H-ras prevent skeletal myoblast differentiation. | None |
| Activated N-ras oncogene in a transformant derived from a rat small intestinal adenocarcinoma induced by 2-aminodipyrido[1,2-a:3 ,2 -d]imidazole. | None |
| Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate. Implications for increased therapeutic ratio of low dose rate irradiation. | None |